Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsHigher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.
Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.
Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.
1.
Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma
2.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
3.
Which Salvage Therapy Is Best for Recurrent Prostate Cancer?
4.
Belzutifan Plus Pembro Approved for Adjuvant RCC
5.
investigating radiation oncology applications of artificial general intelligence.
1.
Exploring the Causes and Treatments of Cysts: A Comprehensive Guide
2.
Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care
3.
Strategic Standards in Hematology for Specialists
4.
Iron Metabolism and Inflammatory Disorders: Mechanisms, Clinical Implications, and Therapeutic Approaches
5.
First-Line Immuno-Hematology Examinations: Essential Diagnostic Tools for Patient Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
5.
Navigating the Complexities of Ph Negative ALL - Part XV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge